Click on the protein name for more information about the protein.
The Score column is the predicted score of interaction between the two proteins
Click on the Evidence link to view a breakdown of the information about the predicted interaction.
Key | |
---|---|
Module Score | Databases |
![]() | Where interaction is observed in another database a link is provided: |
Protein 1 (?) | Protein 2 (?) | Name of Protein 2 | Module Scores (?) | Scores (?) | Evidence (?) | Database (?) | |||
---|---|---|---|---|---|---|---|---|---|
![]() | ![]() | ![]() | ![]() | ||||||
STAT3 | STAT1 | STAT1: Signal transducer and activator of transcription 1-alpha/beta | 3.40E3 | Evidence |
![]() |
||||
STAT3 | STAT5A | STAT5A, STAT5: Signal transducer and activator of transcription 5A | 2.89E3 | Evidence |
![]() |
||||
STAT3 | STAT6 | STAT6: Signal transducer and activator of transcription 6 | 2.69E3 | Evidence | |||||
STAT3 | STAT5B | STAT5B: Signal transducer and activator of transcription 5B | 1.91E3 | Evidence |
![]() |
||||
STAT3 | TEC | TEC, PSCTK4: Tyrosine-protein kinase Tec | 299.0 | Evidence | |||||
STAT3 | JAK2 | JAK2: Tyrosine-protein kinase JAK2 | 299.0 | Evidence |
![]() |
||||
STAT3 | FYN | FYN: Proto-oncogene tyrosine-protein kinase Fyn | 268.0 | Evidence | |||||
STAT3 | KIT | KIT: Mast/stem cell growth factor receptor precursor | 200.0 | Evidence | |||||
STAT3 | PDGFRA | PDGFRA: Alpha-type platelet-derived growth factor receptor precursor | 200.0 | Evidence |
![]() |
||||
STAT3 | PDGFRB | PDGFRB: Beta-type platelet-derived growth factor receptor precursor | 200.0 | Evidence |
![]() |
||||
STAT3 | INSR | INSR: Insulin receptor precursor | 200.0 | Evidence | |||||
STAT3 | BMX | N/A | 156.0 | Evidence |
![]() |
||||
STAT3 | BTK | BTK, AGMX1, ATK, BPK: Tyrosine-protein kinase BTK | 156.0 | Evidence | |||||
STAT3 | JAK1 | 156.0 | Evidence |
![]() |
|||||
STAT3 | SYK | SYK: Tyrosine-protein kinase SYK | 156.0 | Evidence |
![]() |
||||
STAT3 | LCK | LCK: Proto-oncogene tyrosine-protein kinase LCK | 156.0 | Evidence |
![]() |
||||
STAT3 | SRC | SRC, SRC1: Proto-oncogene tyrosine-protein kinase Src | 156.0 | Evidence |
![]() |
||||
STAT3 | INSL3 | JAK3: Tyrosine-protein kinase JAK3 | 119.0 | Evidence |
![]() |
||||
STAT3 | ABL1 | ABL1, ABL, JTK7: Proto-oncogene tyrosine-protein kinase ABL1 | 119.0 | Evidence | |||||
STAT3 | TYK2 | TYK2: Non-receptor tyrosine-protein kinase TYK2 | 119.0 | Evidence | |||||
STAT3 | ZAP70 | ZAP70: Uncharacterized protein ZAP70 | 119.0 | Evidence | |||||
STAT3 | PTK6 | PTK6, BRK: Tyrosine-protein kinase 6 | 119.0 | Evidence | |||||
STAT3 | ERBB2 | ERBB2, HER2, NEU, NGL: Receptor tyrosine-protein kinase erbB-2 precursor | 117.0 | Evidence | |||||
STAT3 | ERBB3 | ERBB3, HER3: Receptor tyrosine-protein kinase erbB-3 precursor | 117.0 | Evidence | |||||
STAT3 | EGFR | EGFR, ERBB1: Epidermal growth factor receptor precursor | 117.0 | Evidence |
![]() ![]() |
||||
STAT3 | CSK | CSK: Tyrosine-protein kinase CSK | 106.0 | Evidence | |||||
STAT3 | PTK2B | PTK2B, FAK2, PYK2, RAFTK: Protein tyrosine kinase 2 beta | 106.0 | Evidence |
![]() |
||||
STAT3 | LYN | LYN: Tyrosine-protein kinase Lyn | 106.0 | Evidence | |||||
STAT3 | FGR | FGR, SRC2: Proto-oncogene tyrosine-protein kinase FGR | 106.0 | Evidence | |||||
STAT3 | KDR | KDR, FLK1: Vascular endothelial growth factor receptor 2 precursor | 104.0 | Evidence | |||||
STAT3 | TEK | TEK, TIE2: Angiopoietin-1 receptor precursor | 89.20 | Evidence | |||||
STAT3 | FGFR3 | FGFR3, JTK4: Fibroblast growth factor receptor 3 precursor | 89.20 | Evidence |
![]() |
||||
STAT3 | FLT1 | FLT1, FLT, FRT: Vascular endothelial growth factor receptor 1 precursor | 79.90 | Evidence |
![]() |
||||
STAT3 | FGFR4 | FGFR4, JTK2, TKF: Fibroblast growth factor receptor 4 precursor | 79.90 | Evidence |
![]() |
||||
STAT3 | ERBB4 | ERBB4, HER4: Receptor tyrosine-protein kinase erbB-4 precursor | 49.40 | Evidence | |||||
STAT3 | NCK2 | NCK2: Cytoplasmic protein NCK2 | 33.90 | Evidence | |||||
STAT3 | CRKL | CRKL: Crk-like protein | 33.90 | Evidence | |||||
STAT3 | DUSP6 | DUSP6, MKP3, PYST1: Dual specificity protein phosphatase 6 | 20.50 | Evidence | |||||
STAT3 | NCK1 | NCK1, NCK: Cytoplasmic protein NCK1 | 20.50 | Evidence | |||||
STAT3 | MAPK3 | MAPK3, ERK1, PRKM3: Mitogen-activated protein kinase 3 | 20.50 | Evidence |
![]() |
||||
STAT3 | GRB2 | GRB2, ASH: Growth factor receptor-bound protein 2 | 20.50 | Evidence | |||||
STAT3 | PIK3R2 | PIK3R2: Phosphatidylinositol 3-kinase regulatory subunit beta | 20.50 | Evidence | |||||
STAT3 | MUSK | MUSK: Muscle, skeletal receptor tyrosine protein kinase precursor | 19.70 | Evidence | |||||
STAT3 | APS | SH2B2, APS: SH2B adapter protein 2 | 19.70 | Evidence | |||||
STAT3 | KHDRBS1 | KHDRBS1, SAM68: KH domain-containing, RNA-binding, signal transduction-associate | 19.00 | Evidence |
![]() |
||||
STAT3 | STAM2 | STAM2: Signal transducing adapter molecule 2 | 17.60 | Evidence | |||||
STAT3 | WAS | WAS, IMD2: Wiskott-Aldrich syndrome protein | 17.60 | Evidence | |||||
STAT3 | CSNK2A1 | CSNK2A1: CSNK2A1 protein | 17.60 | Evidence | |||||
STAT3 | MAP2K2 | MAP2K2, MEK2, MKK2, PRKMK2: Dual specificity mitogen-activated protein kinase ki | 17.60 | Evidence | |||||
STAT3 | RPS6KA2 | RPS6KA2, RSK3: Ribosomal protein S6 kinase alpha-2 | 17.60 | Evidence | |||||
STAT3 | MKNK1 | MKNK1, MNK1: MAP kinase-interacting serine/threonine-protein kinase 1 | 17.60 | Evidence | |||||
STAT3 | RAF1 | RAF1, RAF: RAF proto-oncogene serine/threonine-protein kinase | 17.60 | Evidence | |||||
STAT3 | DUSP16 | DUSP16, KIAA1700, MKP7: Dual specificity protein phosphatase 16 | 17.60 | Evidence | |||||
STAT3 | PTPN2 | PTPN2, PTPT: Tyrosine-protein phosphatase non-receptor type 2 | 15.10 | Evidence |
![]() |
||||
STAT3 | DUSP1 | DUSP1, CL100, MKP1, PTPN10, VH1: Dual specificity protein phosphatase 1 | 15.10 | Evidence | |||||
STAT3 | BLNK | BLNK, BASH, SLP65: B-cell linker protein | 15.00 | Evidence | |||||
STAT3 | PTPN6 | PTPN6, HCP, PTP1C: Tyrosine-protein phosphatase non-receptor type 6 | 15.00 | Evidence | |||||
STAT3 | SOCS3 | SOCS3, CIS3, SSI3: Suppressor of cytokine signaling 3 | 15.00 | Evidence | |||||
STAT3 | MYO3A | MYO3A: Myosin IIIA | 15.00 | Evidence | |||||
STAT3 | SPTA1 | SPTA1, SPTA: Spectrin alpha chain, erythrocyte | 15.00 | Evidence | |||||
STAT3 | RASA1 | RASA1, RASA: Ras GTPase-activating protein 1 | 15.00 | Evidence | |||||
STAT3 | IRS1 | IRS1: Insulin receptor substrate 1 | 15.00 | Evidence | |||||
STAT3 | SH3BP2 | SH3BP2: Uncharacterized protein SH3BP2 | 15.00 | Evidence | |||||
STAT3 | CTTN | CTTN, EMS1: Src substrate cortactin | 15.00 | Evidence | |||||
STAT3 | CBL | CBL, CBL2, RNF55: E3 ubiquitin-protein ligase CBL | 13.50 | Evidence | |||||
STAT3 | RPS6KA5 | RPS6KA5, MSK1: Ribosomal protein S6 kinase alpha-5 | 13.40 | Evidence |
![]() |
||||
STAT3 | LATS2 | LATS2, KPM: Serine/threonine-protein kinase LATS2 | 13.40 | Evidence | |||||
STAT3 | DYRK3 | N/A | 13.40 | Evidence | |||||
STAT3 | WASPIP | N/A | 13.40 | Evidence | |||||
STAT3 | AKT1 | AKT1, PKB, RAC: RAC-alpha serine/threonine-protein kinase | 13.40 | Evidence | |||||
STAT3 | CAMK2D | CAMK2D, CAMKD: Calcium/calmodulin-dependent protein kinase type II delta chain | 13.40 | Evidence | |||||
STAT3 | WASL | WASL: Neural Wiskott-Aldrich syndrome protein | 13.40 | Evidence | |||||
STAT3 | LCP1 | LCP1, PLS2: Plastin-2 | 13.40 | Evidence | |||||
STAT3 | MAPK1 | MAPK1, ERK2, PRKM1, PRKM2: Mitogen-activated protein kinase 1 | 13.40 | Evidence |
![]() |
||||
STAT3 | PIK3CB | PIK3CB, PIK3C1: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit | 13.40 | Evidence | |||||
STAT3 | VAV1 | VAV1, VAV: Proto-oncogene vav | 13.40 | Evidence | |||||
STAT3 | GHR | GHR: Growth hormone receptor precursor | 13.00 | Evidence |
![]() |
||||
STAT3 | PTPN1 | PTP1B, PTPN1: Tyrosine-protein phosphatase non-receptor type 1 | 13.00 | Evidence | |||||
STAT3 | EPOR | EPOR: Erythropoietin receptor precursor | 13.00 | Evidence | |||||
STAT3 | CCR5 | CCR5: CCR5 receptor (Fragment) | 13.00 | Evidence |
![]() |
||||
STAT3 | IL2RB | IL2RB: Interleukin-2 receptor subunit beta precursor | 13.00 | Evidence |
![]() |
||||
STAT3 | STAT4 | STAT4: Signal transducer and activator of transcription 4 | 12.80 | Evidence | |||||
STAT3 | FOSL2 | FOSL2, FRA2: Fos-related antigen 2 | 11.20 | Evidence | |||||
STAT3 | FOS | FOS, G0S7: Proto-oncogene protein c-fos | 11.20 | Evidence | |||||
STAT3 | PTPRC | PTPRC, RP11-553K8.4-001, hCG_1811178: Protein tyrosine phosphatase, receptor typ | 9.92 | Evidence | |||||
STAT3 | CD247 | CD247, CD3Z, T3Z, TCRZ: T-cell surface glycoprotein CD3 zeta chain precursor | 9.92 | Evidence | |||||
STAT3 | CEBPA | CEBPA: CCAAT/enhancer-binding protein alpha | 9.92 | Evidence | |||||
STAT3 | ETS2 | ETS2: Protein C-ets-2 | 9.92 | Evidence | |||||
STAT3 | DUSP3 | DUSP3, VHR: Dual specificity protein phosphatase 3 | 9.92 | Evidence | |||||
STAT3 | STAT2 | STAT2: Signal transducer and activator of transcription 2 | 9.92 | Evidence | |||||
STAT3 | CSF2RB | CSF2RB, IL3RB, IL5RB: Cytokine receptor common beta chain precursor | 9.92 | Evidence |
![]() |
||||
STAT3 | IFNGR1 | IFNGR1: Interferon-gamma receptor alpha chain precursor | 9.92 | Evidence | |||||
STAT3 | HLA-DMB | HLA-DMB, DMB, RING7: HLA class II histocompatibility antigen, DM beta chain prec | 9.92 | Evidence | |||||
STAT3 | LCP2 | LCP2: Lymphocyte cytosolic protein 2 | 9.92 | Evidence | |||||
STAT3 | PRKR | EIF2AK2, PKR, PRKR: Interferon-induced, double-stranded RNA-activated protein ki | 9.92 | Evidence |
![]() |
||||
STAT3 | CD79B | CD79B, B29, IGB: B-cell antigen receptor complex-associated protein beta-chain p | 9.92 | Evidence | |||||
STAT3 | PHC2 | PHC2, EDR2, PH2: Polyhomeotic-like protein 2 | 9.92 | Evidence | |||||
STAT3 | PPP2CA | PPP2CA: Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform | 8.92 | Evidence | |||||
STAT3 | CBLB | CBLB, RNF56, Nbla00127: E3 ubiquitin-protein ligase CBL-B | 8.89 | Evidence | |||||
STAT3 | SOS1 | SOS1: Son of sevenless homolog 1 | 8.89 | Evidence | |||||
STAT3 | ROBO1 | ROBO1, DUTT1: Roundabout homolog 1 precursor | 8.89 | Evidence | |||||
STAT3 | PTPRF | PTPRF, LAR: Receptor-type tyrosine-protein phosphatase F precursor | 8.89 | Evidence | |||||
STAT3 | BRCA2 | BRCA2, FACD, FANCD1: Breast cancer type 2 susceptibility protein | 7.59 | Evidence | |||||
STAT3 | CRIP2 | CRIP2, CRP2: Cysteine-rich protein 2 | 7.59 | Evidence | |||||
STAT3 | CTLA4 | CTLA4, CD152: Cytotoxic T-lymphocyte protein 4 precursor | 6.14 | Evidence | |||||
STAT3 | RPS6KA3 | RPS6KA3, ISPK1, RSK2: Ribosomal protein S6 kinase alpha-3 | 5.61 | Evidence | |||||
STAT3 | CXCR4 | CXCR4: C-X-C chemokine receptor type 4 | 5.28 | Evidence |
![]() |
||||
STAT3 | CREB1 | CREB1: cAMP response element-binding protein | 5.26 | Evidence | |||||
STAT3 | HSF1 | HSF1, HSTF1: Heat shock factor protein 1 | 5.26 | Evidence | |||||
STAT3 | CREBBP | CREBBP, CBP: CREB-binding protein | 5.26 | Evidence |
![]() ![]() |
||||
STAT3 | JUN | JUN: Transcription factor AP-1 | 5.26 | Evidence |
![]() |
||||
STAT3 | GCN5L2 | GCN5L2, GCN5, HGCN5: General control of amino acid synthesis protein 5-like 2 | 5.26 | Evidence | |||||
STAT3 | BARD1 | BARD1: BRCA1-associated RING domain protein 1 | 4.97 | Evidence | |||||
STAT3 | PHB2 | PHB2, BAP, REA: Prohibitin-2 | 4.76 | Evidence | |||||
STAT3 | HPCAL1 | HPCAL1, BDR1: Hippocalcin-like protein 1 | 4.76 | Evidence | |||||
STAT3 | BCAR1 | BCAR1, CAS, CRKAS: Breast cancer anti-estrogen resistance protein 1 | 4.68 | Evidence | |||||
STAT3 | GRB10 | N/A | 4.68 | Evidence | |||||
STAT3 | CRK | CRK: Proto-oncogene C-crk | 4.68 | Evidence | |||||
STAT3 | NR3C1 | NR3C1, GRL: Glucocorticoid receptor | 4.48 | Evidence |
![]() |
||||
STAT3 | CHGB | CHGB, SCG1: Secretogranin-1 precursor | 4.48 | Evidence | |||||
STAT3 | RELA | RELA, NFKB3: Transcription factor p65 | 4.48 | Evidence |
![]() |
||||
STAT3 | TNFRSF1A | TNFRSF1A, TNFAR, TNFR1: Tumor necrosis factor receptor superfamily member 1A pre | 4.48 | Evidence | |||||
STAT3 | CEBPB | CEBPB, TCF5, PP9092: CCAAT/enhancer-binding protein beta | 4.48 | Evidence | |||||
STAT3 | FADD | FADD, MORT1: Protein FADD | 4.48 | Evidence | |||||
STAT3 | CALM2 | CALM1, CALM, CALM2, CAM2, CALM3, CALML2, CAM, CAMB, CAM3, CAM1, CAMC, CAMIII: Ca | 4.26 | Evidence | |||||
STAT3 | ANXA6 | ANXA6, ANX6: Annexin A6 | 4.02 | Evidence | |||||
STAT3 | CNTN2 | CNTN2, AXT, TAG1, TAX1: Contactin-2 precursor | 4.02 | Evidence | |||||
STAT3 | ETS1 | ETS1, EWSR2: Protein C-ets-1 | 4.01 | Evidence | |||||
STAT3 | BRCA1 | BRCA1, RNF53: Breast cancer type 1 susceptibility protein | 4.01 | Evidence |
![]() |
||||
STAT3 | TERF2IP | TERF2IP, RAP1, PP8000: Telomeric repeat-binding factor 2-interacting protein 1 | 3.64 | Evidence | |||||
STAT3 | CTDP1 | CTDP1, FCP1: RNA polymerase II subunit A C-terminal domain phosphatase | 3.64 | Evidence | |||||
STAT3 | ESRRA | ESRRA, ERR1, ESRL1, NR3B1: Steroid hormone receptor ERR1 | 3.64 | Evidence | |||||
STAT3 | SHC3 | SHC3, NSHC, SHCC: SHC-transforming protein 3 | 3.31 | Evidence | |||||
STAT3 | MCM3 | MCM3: DNA replication licensing factor MCM3 | 3.26 | Evidence | |||||
STAT3 | VDR | VDR, NR1I1: Vitamin D3 receptor | 3.26 | Evidence | |||||
STAT3 | ARHGEF1 | ARHGEF1: Rho guanine nucleotide exchange factor 1 | 3.18 | Evidence | |||||
STAT3 | NMI | NMI: N-myc-interactor | 3.18 | Evidence |
![]() ![]() |
||||
STAT3 | RASGRF2 | RASGRF2: Ras protein-specific guanine nucleotide-releasing factor 2 (Fragment) | 3.18 | Evidence | |||||
STAT3 | COPA | COPA: Coatomer subunit alpha | 2.99 | Evidence | |||||
STAT3 | ABCF1 | N/A | 2.54 | Evidence | |||||
STAT3 | VCPIP1 | VCPIP1, KIAA1850, VCIP135: Deubiquitinating protein VCIP135 | 2.54 | Evidence | |||||
STAT3 | NFKBIA | NFKBIA, IKBA, MAD3, NFKBI: NF-kappa-B inhibitor alpha | 2.54 | Evidence | |||||
STAT3 | USP10 | USP10, KIAA0190: Ubiquitin carboxyl-terminal hydrolase 10 | 2.54 | Evidence | |||||
STAT3 | CHUK | N/A | 2.54 | Evidence | |||||
STAT3 | MAPK7 | mitogen-activated protein kinase 7 isoform 1 | 2.54 | Evidence | |||||
STAT3 | STIP1 | STIP1: Stress-induced-phosphoprotein 1 | 2.54 | Evidence | |||||
STAT3 | DUSP2 | DUSP2, PAC1: Dual specificity protein phosphatase 2 | 2.50 | Evidence |